(Published on 26 October 2017) The release and presentation materials are now available.
|10/26/2017||Composition of the Nomination Committee of Orion Corporation|
|10/26/2017||Orion Group Interim Report January-September 2017|
|8/1/2017||146,000 Orion Corporation A shares converted into B shares|
|7/19/2017||Orion Group Half-Year Financial Report January-June 2017|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs, contract manufacturing and diagnostic tests.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.